Dianthus Therapeutics made waves in September when it announced data from its lead program claseprubart in generalized Myasthenia Gravis - CEO Marino Garcia walks us through the program and data
He describes the asset, which has an extended half life and is designed to only inhibit the active form of C1s, and contrasts it with other medicines on the market today. Plus, the rationale for in-licensing a bispecific fusion protein that targets BDCA2 and BAFF/APRIL.
Dec 15
OrbiMed's Carl Gordon shares his take on biotech's 2025 and what could be ahead for the sector in 2026
He discusses the causes of the rapid bounce biotech has witnessed over the last handful of months, his take on 2026, including the IPO environment, private vs public companies, areas of interest, and more.
Dec 15
CREATE Medicines' platform allows it to program CARs into multiple immune cell types inside the body, and is redosable. While this includes CAR-T, they believe that "in vivo is more than T-cells."
Co-Founder and CEO Daniel Getts walks us through the platform, which is delivered via LNPs. The lead programs target TROP2, HER2, and GPC3.
Dec 12
The leaders of London based LabGenius Therapeutics discuss a recent ESMO IO poster for their Nectin-4 x CD3 T-cell engager, and a new expanded collaboration with Sanofi on antibody optimization
CEO James Field and CSO Angus Sinclair discuss the Nectin-4 bi-specific, which is meant to have increased selectivity and potency and will compete with ADCs that are already on the market. Plus, how they are using their ML/AI expertise to help Sanofi with new programs.
Dec 11
Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today
Founder and CEO Michelle Lee highlights the key distinction between Medra and other automated lab equipment, which is that Medra's platform is designed to sense and understand its environment and use that knowledge to make its own intelligent decisions.
Dec 11
Kymera Therapeutics' Founder & CEO Nello Mainolfi recaps Monday's STAT6 data and discusses the next steps in development
He talks about Kymera's dosing methodology, and recaps the data from a degradation, biomarker, and clinical outcomes standpoint. Plus, next steps in STAT6, and thoughts on the platform in general and the field more broadly.
Dec 10
.png){kind=logo}
